Why is the Recce (ASX:RCE) share price soaring 14%?

The Recce share price is flying today on news the company has had encouraging results in its COVID-19 drug trials. Let's take a look.

| More on:
Young girl wearing a suit and tie with rocket wings looks to the sky representing the highest traded stocks today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been soaring up today. Recce shares jumped up more than 14% on news that the company has seen encouraging results in the treatment against the COVID-19 virus. The release comes on the same day that Pfizer Inc (NYSE: PFE) announced its vaccine success.

The Recce share price has risen 14.21% at the time of writing, vaulting its shares to $1.08.

What does Recce do?

Recce is involved in drug discovery and development business. It aims to commercialise a new class of synthetic antibiotics that target a wide range of diseases to address the global health challenge of antibiotic-resistant superbugs.

The group operates solely in research and development, and is located in both Australia and the United States.

COVID-19 trial success

Today the Recce share price is flying on the news that it saw encouraging results of its primary drug, Recce 327 against COVID-19. R327, a synthetic anti-infective drug, showed encouraging efficacy in an in-vitro screening assay against the virus.

FDA-approved R327 has traditionally been developed for the treatment of blood infections and sepsis. Infections that are derived from E. coli and S. aureus bacteria. However, earlier this year it was announced that the drug may also be effective against COVID-19.

As the drug showed encouraging inhibition against the virus it is now advancing to Stage 1b. This stage will be under way in near weeks.

Whilst the company is delighted by the results, it notes that preliminary and further testing must be completed before the drug can be announced as fully effective.

Recce non-executive chair John Prendergast was pleased, saying:

We're highly encouraged by the results from this study, which indicate anti-viral activity of R327 and, in particular, highlight the potential potency of our lead candidate against SARS-CoV-2 . We are interested in seeing the next stage and look forward to continuing research on the effectiveness of R327 with the team at the Doherty Institute.

Should you invest $1,000 in Block right now?

Before you buy Block shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Block wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young woman in a red polka-dot dress holds an old-fashioned green telephone set in one hand and raises the phone to her ear representing the Telstra share price and the opportunity for investors in FY23
Opinions

The Telstra share price hit a 52-week high this week, is it still a buy?

Is buying Telstra still a good call after its rise?

Read more »

gaming asx share price rise represented by slot machine paying jackpot
Share Market News

Based on recent US casino trends, does Macquarie prefer Light & Wonder or Aristocrat shares?

The metrics of one of these ASX gaming shares look far more appealing, according to the top broker.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Friday

Will the market finish the week on a high? Let's find out.

Read more »

Person pressing the sell button on a smartphone.
Broker Notes

Sell alert! 3 ASX shares the brokers are calling time on

Brokers say it's time to hit the sell button on these ASX shares.

Read more »

A couple smile as they look at a pregnancy test.
Share Market News

After the recent debacle, what price target does Macquarie have on Monash IVF shares?

Supported by strong industry tailwinds, this ASX stock could be worth a second look.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was the ASX's fourth day of gains for the week today.

Read more »

A happy couple drinking red wine in a vineyard.
Best Shares

5 ASX 200 shares just upgraded to strong buy ratings

The experts say these 5 shares are set to rise over the next 12 months.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Share Market News

What is next for ASX 200 shares after last month's upheaval?

Macquarie reveals its outlook for ASX 200 shares in May in a new research note published today.

Read more »